Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Alpelisib and Fulvestrant in PIK3CA-mutated ER-Positive Endometrioid Endometrial Cancers
NCT05154487Phase 2Active, not recruiting
- Sponsor
- GOG Foundation
- Start
- Sep 2024
- Primary completion
- May 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of alpelisib in endometrial cancer (EC), sponsored by GOG Foundation. Started Sep 2024; status: active, not recruiting.
02
Drugs
alpelisib
03
Conditions
endometrial cancer (EC)
Beyond the preview
Go deeper on NCT05154487.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05154487.